Serial No.:

09/902,48

Filing Date:

July 9, 2001

Please delete the last-filed "Sequence Listing" and insert there for the enclosed 32-page text entitled "SEQUENCE LISTING."

REMARKS

The above amendment to the specification is submitted for the Examiner's consideration should he or she deem it to be necessary to replace the existing Sequence Listing and to add proper reference to the sequences on page 29. Attached hereto is a marked-up version of the changes made to the specification by the proposed amendment. The attached page is captioned "Version with markings to show changes made."

Entry of this amendment is respectfully requested if the Examiner considers it necessary in order for the specification to be in complete compliance with the sequence rules. The amendments are made in adherence with 37 C.F.R. § 1.821-1.825. This amendment is accompanied by a floppy disk containing the above named sequence, SEQUENCE ID NUMBERS 1-13 in computer readable form, and a paper copy of the sequence information. The computer readable sequence listing was prepared through use of the software program "PatentIn" provided by the PTO. The information contained in the computer readable disk is identical to that of the paper copy. This amendment contains no new matter. Applicant submits that this amendment, the accompanying computer readable sequence listing, and the paper copy thereof serve to place this application in a condition of adherence to the rules 37 C.F.R. § 1.821-1.825.

Please direct any calls in connection with this application to the undersigned at (415) 781-1989.

Respectfully submitted,

DORSEY & WHITNEY LLP

Renee M. Kosslak, Reg/No. 47,717 for Robin M. Silva, Reg. No. 38,304

Filed under 37 C.F.R. § 1.34(a)

Dated: 11/4/02

Customer Number: 32940

Four Embarcadero Center, Suite 3400

San Francisco, CA 94111-4187

Telephone:

(415) 781-1989

Facsimile:

(415) 398-3249

1097002 1.DOC

- 3 -

Serial No.:

09/902,48

Filing Date:

July 9, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Paragraph beginning at page 28, line 34, has been amended as follows:

—In a preferred emodiment embodiment, the amino acid alterations (including substitutions, insertions and deletions) are non-contiguous. By noncontiguous herein is meant that the inserted mutations are not completely continuous along the peptide backbone. At least one amino acid must remain unchanged between two changed amino acids, however, not all changed amino acids need to be noncontiguous. Additionally, regions (areas of contiguous changed or mutated residues) that are noncontiguous are not doubly counted to be noncontiguous with each other if both positions have been already defined as noncontiguous with respect to the same third region. For instance, changing

LVLVLVL (SEQ ID NO:8) to LPLPLVL (SEQ ID NO:9) would result in a single noncontiguous change of two amino acids, while LVLVLVL (SEQ ID NO:8) to LPLPLPL (SEQ ID NO:10) would result in two noncontiguous changes (the left P and right P each being noncontiguous with the center P, while the left and right P are also noncontiguous with each other they have both already been counted in a noncontiguous sequence with respect to the center P.) Likewise, LVLVLVL (SEQ ID NO:8) to LPPVLPP (SEQ ID NO:11) is a contiguous change and LVLVLVL (SEQ ID NO:8) to LPPVLPP (SEQ ID NO:12) is a single noncontiguous change. However, LVLVLVL (SEQ ID NO:8) to PPLPPVP (SEQ ID NO:13) would be counted as two noncontiguous changes.—

The enclosed 32-page text entitled "SEQUENCE LISTING" was inserted into the specification.